What Is eConsent? Electronic Consent in Clinical Trials

eConsent, or electronic informed consent, is the digital version of the informed consent process used in clinical research. Instead of reviewing and signing printed forms, participants review study information through a secure electronic platform on a computer, tablet, or mobile device, confirm their understanding, and provide consent using an electronic signature.

eConsent serves the same ethical purpose as traditional informed consent: participants must receive enough relevant information to make a voluntary, informed decision about joining a study. The difference is how that information is delivered, reviewed, documented, and managed. 

You may also hear eConsent described as virtual consent or digital consent. These terms generally refer to using electronic technology to support some or all of the informed consent process. 

How Does eConsent Work?

Although the technology behind eConsent can be sophisticated, the participant experience is relatively straightforward. A typical process looks like this: 

This workflow can support fully remote consent as well as on-site “handoff” workflows. In a handoff model, participants can use a study device to complete the digital consent process while a clinician or other authorized staff member is available to guide them. 

eConsent vs. Paper Consent: What’s the Difference?

Paper and electronic consent are designed to accomplish the same fundamental goal. When properly implemented and accepted by the applicable authorities and ethics committee, eConsent can satisfy the same informed consent requirements as a paper-based process. The main differences involve delivery, documentation, flexibility, and how the participant interacts with the information. FDA and OHRP guidance specifically addresses the use of electronic systems and processes for obtaining informed consent.

eConsent does not change what informed consent requires — it changes how reliably and consistently those requirements can be met.

Benefits of eConsent

The biggest advantages of eConsent go beyond replacing paper forms. When designed well, it can make the consent process more accessible, engaging, and manageable for both participants and study teams.

Improved Participant Comprehension

Traditional paper forms routinely run well above the reading level of the populations they’re given to, which means the burden of comprehension falls on whoever happens to be in the room explaining it. eConsent narrows that variability by delivering the same content to every participant. It includes multimedia explanations and plain language content that make dense medical information easier to absorb than a printed page of legal and clinical terminology. That distinction matters beyond the consent visit itself: better understanding at enrollment tends to broaden participation as the study goes on.  

Broader Access and Faster Enrollment

Because eConsent doesn’t require a participant to travel to a site purely to sign paperwork, it opens enrollment to a wider geographic pool. That matters most for participants dealing with mobility limitations, transportation barriers, or schedules that make an extra site visit difficult to justify. 

A participant can review materials at home, on their own timeline, and consult family or a caregiver before signing. Widening the catchment area also has a direct bearing on representativeness, allowing space for participants generally excluded by a travel requirement.    

Reduced Administrative Burden

eConsent removes printing, scanning, filing, and manually tracking signed forms from the process entirely. It also diminishes the risk of a participant signing a version of the form that’s already been superseded. Using an outdated consent form is among the more common and more consequential findings in clinical trial inspections — and on paper it is difficult to prevent across a multi-site study.  When a protocol is amended, reconsent workflows can be automated rather than rebuilt from scratch each time. 

The administrative time recovered is not trivial: coordinator hours spent on document handling are hours not spent on participant follow-up, and in a study with high reconsent frequency that difference is measurable in retention. 

Stronger Documentation and Audit Readiness

Consent documentation is among the first things inspectors examine and among the most frequently cited deficiency areas in FDA warning letters to clinical investigators. Every step of an eConsent session is timestamped and attributable — not just the signature, but the content that was displayed and when. Signed forms live in one central system instead of scattered across individual site file rooms, which means an inspector can be shown a complete consent record without anyone having to reconstruct a paper trail after the fact. 

On the other hand, a paper process can produce a signed form without producing any evidence of what preceded the signature, which leaves study teams defending a process they can only describe rather than demonstrate. 

Better Support for Decentralized and Hybrid Trials

For many decentralized studies, eConsent is the first digital touchpoint a participant has with the trial, which makes it an early signal of what the rest of their experience will feel like. It also tends to connect naturally to the other digital pieces of a decentralized or hybrid study, including virtual visits and ePRO/eCOA data collection running on the same platform. 

A consent process that feels confusing or unreliable sets an expectation the rest of the study has to work against, while one that feels clear and well-built tends to reduce friction. A single platform means a participant’s consent status is visible in the same place as their data.  

eConsent and Regulatory Compliance

eConsent has to satisfy two sets of requirements at the same time: the informed consent standards that apply to any clinical study, and the electronic records requirements that apply specifically to digital systems.

• US requirements: 21 CFR Part 50 governs informed consent, while 21 CFR Part 11 covers electronic records and electronic signatures; FDA and OHRP have both issued specific guidance on using electronic informed consent.
• International requirements: ICH GCP E6(r3) sets expectations for consent broadly, and IRBs or ethics committees still need to approve the consent materials themselves — the EU Clinical Trials Regulations and EU Guidelines on electronic data in clinical trials add further requirements for computerized systems used in EU trials.
• Data privacy: GDPR and HIPAA govern how participant data is handled within an eConsent platform, separate from the consent content itself.

In practice, this means an IRB needs to review the actual eConsent presentation, identify verification, comprehension documentation, and the audit trail — not just the consent text. Requirements vary by region, so sponsors running global studies should confirm local acceptance of remote consent before deployment.

Common Concerns About eConsent

Sponsors and sites considering eConsent tend to raise similar questions, most of them centered on regulatory acceptance, participant access, and what happens when something goes wrong. The answers below broadly address the concerns that come up most consistently in evaluation conversations.  

“Will participants find it harder to ask questions?”

Not necessarily. Video calls, telephone support, and built-in question-and-answer features can preserve the interaction between participants and study staff. The technology should support the conversation, not replace it.

“What about participants who aren’t comfortable with technology?”

A participant-centered system should offer simple navigation, device flexibility, and support for on-site handoff workflows. Where appropriate, study teams may also need a paper fallback.

“Is it secure?”

Security depends on the platform and its implementation. Strong systems can use measures such as encryption, authentication, role-based access controls, and audit trails to protect information and limit access to authorized users.

“Will our IRB accept it?”

The safest approach is to involve the IRB or ethics committee early. FDA/OHRP guidance makes clear that the electronic process itself matters, not simply the content of the consent form.

“Is it worth it for a small study?”

There is no universal break-even point. The calculation depends on participant numbers, number of sites, geographic reach, expected amendments, reconsent requirements, and how much administrative work the study team currently spends managing paper consent.

How to Implement eConsent

Rolling out eConsent tends to go more smoothly as a sequence rather than an all-at-once switch. Start by confirming regional and IRB acceptance of remote consent for your study population. From there, convert the consent text into plain language and identify where multimedia genuinely adds clarity. 

• Build comprehension checks around the elements that study participants most commonly misinterpret.
• Submit the full eConsent experience — not just the underlying text — for IRB review.
• Plan for accessibility across languages, literacy levels, and devices from the start, rather than retrofitting it later.

A common mistake is treating eConsent as little more than a PDF with a signature field. That approach may digitize paperwork without taking advantage of the technology. Other pitfalls include overlooking accessibility, failing to plan for participants who need additional assistance, and waiting too long to involve the IRB. Site staff still need training on both remote and handoff workflows, and it helps to define the reconsent process before the first amendment arrives.

TrialKit eConsent: A Participant-Centered Consent Experience

TrialKit eConsent is built as part of a unified eClinical platform, connecting consent directly to EDC, ePRO/eCOA, and virtual visits within the same system rather than as a standalone tool. It offers a mobile-friendly design, multimedia explanations, and built-in comprehension checks, along with handoff mode for on-site consent, automatic participant copies, and a complete audit trail behind every session, giving study teams a consent process that’s easier for participants to navigate and easier for sponsors to defend.

FAQs About eConsent in Clinical Trials

What is eConsent?

eConsent, or electronic informed consent, is the process of delivering, reviewing, and signing clinical trial consent documents through a secure digital platform rather than on paper. Participants access consent materials on a tablet, computer, or smartphone, review the information at their own pace with the help of multimedia explanations, and sign electronically. eConsent carries the same legal and ethical weight as paper consent and serves the same purpose: ensuring participants are fully informed before joining a study.

Is eConsent legally valid?

Yes, eConsent is accepted by the FDA and other regulatory bodies when it meets the same informed consent standards that apply to paper, along with requirements for electronic records and electronic signatures such as 21 CFR Part 11. The consent materials and the way they are presented must also be approved by the reviewing IRB or ethics committee. Acceptance of fully remote consent can vary by country, so studies should confirm local requirements before deployment.

What is the difference between eConsent and paper consent?

Both processes must meet identical informed consent requirements, so the difference is in delivery and documentation rather than legal standing. Paper consent presents static text, usually during a single in-person visit, and relies on manual filing and version tracking. eConsent delivers the same information digitally, with videos, images, and glossary support, allows participants to review at their own pace from any location, and automatically records a timestamped audit trail of what was presented and when consent was given.

Does eConsent improve participant comprehension?

eConsent gives study teams tools that paper cannot provide, including plain-language content, video explanations, glossary definitions for technical terms, and interactive knowledge checks that confirm understanding before a participant signs. Because participants can review materials at their own pace and revisit sections they find confusing, they tend to arrive at the signature step better informed. Comprehension checks also give sites documented evidence that understanding was verified rather than assumed.

Can participants consent remotely?

Yes. Remote or virtual consent allows participants to review and sign consent forms from home using a secure link sent by email or through a mobile app, often paired with a video call so they can ask questions of study staff. This is a defining capability for decentralized and hybrid trials, where reducing site visits is a core objective. Some regions and IRBs have specific requirements around identity verification for remote consent, so confirm expectations during protocol planning.

 How does eConsent handle audit trails?

eConsent platforms automatically record a timestamped, attributable log of the entire consent process, including which version of the form was presented, what content the participant viewed, how long they spent, the results of any comprehension checks, and when the electronic signature was applied. During an inspection, it provides a complete account of the consent process without requiring the site to reconstruct a paper trail.

Is eConsent secure?

Reputable eConsent platforms protect participant data through encrypted transmissions and storage, authenticated user access, and role-based permissions that limit who can view or modify consent records. Systems used in regulated research are validated and designed to meet 21 CFR Part 11 requirements, along with privacy frameworks such as GDPR and HIPAA, where applicable. Sponsors should request validation documentation and security details from any vendor during evaluation

What happens when a protocol is amended?

When a protocol changes in a way that affects participants, they must be reconsented using the updated form. With paper, this means reprinting materials, tracking who has signed which version, and often scheduling additional visits. eConsent systems handle this by serving the current approved version automatically, notifying affected participants, and tracking reconsent status in real time, which substantially reduces the risk of a participant remaining on an outdated consent version.

What happens when a protocol is amended?

When a protocol changes in a way that affects participants, they must be reconsented using the updated form. With paper, this means reprinting materials, tracking who has signed which version, and often scheduling additional visits. eConsent systems handle this by serving the current approved version automatically, notifying affected participants, and tracking reconsent status in real time, which substantially reduces the risk of a participant remaining on an outdated consent version.

How long does it take to implement eConsent?

Implementation timelines depend on the complexity of the consent materials, how much multimedia content needs to be produced, and how quickly the IRB reviews the submission. The build itself is often the shortest part of the process. Teams that underestimate the timeline usually do so because they submit to the IRB late or begin converting consent text into plain language too close to study start, so both should be scheduled early.

Is eConsent only for decentralized trials?

No. eConsent is frequently associated with decentralized and hybrid studies because it enables remote enrollment, but it delivers value in traditional site-based trials as well. In conventional studies, it replaces stacks of printed forms and manual record-keeping, eliminates version control problems, and improves audit readiness, all without changing where the consent conversation takes place.